London
· Delayed Price · Currency is GBP · Price in USD Axsome Therapeutics Statistics
Total Valuation
Axsome Therapeutics has a market cap or net worth of GBP 4.02 billion. The enterprise value is 3.91 billion.
| Market Cap | 4.02B |
| Enterprise Value | 3.91B |
Important Dates
The next estimated earnings date is Thursday, February 20, 2025.
| Earnings Date | Feb 20, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +7.10% |
| Shares Change (QoQ) | +1.19% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 36.23M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 166.70 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -16.87 |
| EV / Sales | 14.24 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -39.50 |
Financial Position
The company has a current ratio of 2.44, with a Debt / Equity ratio of 2.07.
| Current Ratio | 2.44 |
| Quick Ratio | 2.30 |
| Debt / Equity | 2.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.45 |
| Interest Coverage | -48.58 |
Financial Efficiency
Return on equity (ROE) is -171.61% and return on invested capital (ROIC) is -41.52%.
| Return on Equity (ROE) | -171.61% |
| Return on Assets (ROA) | -26.44% |
| Return on Capital (ROIC) | -41.52% |
| Revenue Per Employee | 416,018 |
| Profits Per Employee | -382,213 |
| Employee Count | 545 |
| Asset Turnover | 0.58 |
| Inventory Turnover | 2.49 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +15.83% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +15.83% |
| 50-Day Moving Average | 92.76 |
| 200-Day Moving Average | 84.84 |
| Relative Strength Index (RSI) | 59.85 |
| Average Volume (20 Days) | 1,480 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 9.63 |
Income Statement
In the last 12 months, Axsome Therapeutics had revenue of GBP 252.52 million and -232.00 million in losses. Loss per share was -4.87.
| Revenue | 252.52M |
| Gross Profit | 230.02M |
| Operating Income | -183.45M |
| Pretax Income | -232.25M |
| Net Income | -232.00M |
| EBITDA | -182.51M |
| EBIT | -183.45M |
| Loss Per Share | -4.87 |
Balance Sheet
The company has 244.23 million in cash and 143.48 million in debt, giving a net cash position of 100.75 million.
| Cash & Cash Equivalents | 244.23M |
| Total Debt | 143.48M |
| Net Cash | 100.75M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 69.31M |
| Book Value Per Share | 1.43 |
| Working Capital | 211.09M |
Cash Flow
In the last 12 months, operating cash flow was -98.91 million and capital expenditures -184,287, giving a free cash flow of -99.09 million.
| Operating Cash Flow | -98.91M |
| Capital Expenditures | -184,287 |
| Free Cash Flow | -99.09M |
| FCF Per Share | n/a |
Margins
Gross margin is 91.09%, with operating and profit margins of -72.65% and -91.87%.
| Gross Margin | 91.09% |
| Operating Margin | -72.65% |
| Pretax Margin | -91.97% |
| Profit Margin | -91.87% |
| EBITDA Margin | -72.28% |
| EBIT Margin | -72.65% |
| FCF Margin | n/a |
Dividends & Yields
Axsome Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.10% |
| Shareholder Yield | -7.10% |
| Earnings Yield | -5.77% |
| FCF Yield | -2.46% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Axsome Therapeutics has an Altman Z-Score of 1.89. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.89 |
| Piotroski F-Score | n/a |